TuHURA Biosciences (NASDAQ:HURA) vs. Lakeshore Biopharma (NASDAQ:LSB) Head-To-Head Contrast

Lakeshore Biopharma (NASDAQ:LSB) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Volatility & Risk

Lakeshore Biopharma has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Earnings and Valuation

This table compares Lakeshore Biopharma and TuHURA Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakeshore Biopharma	$672.27 million	0.02	-$61.09 million	N/A	N/A
TuHURA Biosciences	N/A	N/A	-$8.32 million	N/A	N/A

TuHURA Biosciences has lower revenue, but higher earnings than Lakeshore Biopharma.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Lakeshore Biopharma and TuHURA Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakeshore Biopharma	0	0	0	0	0.00
TuHURA Biosciences	0	0	3	1	3.25

TuHURA Biosciences has a consensus target price of $12.67, suggesting a potential upside of 210.46%. Given TuHURA Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe TuHURA Biosciences is more favorable than Lakeshore Biopharma.

Profitability

This table compares Lakeshore Biopharma and TuHURA Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakeshore Biopharma	N/A	N/A	N/A
TuHURA Biosciences	N/A	N/A	-152.88%

Institutional and Insider Ownership

52.6% of Lakeshore Biopharma shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

TuHURA Biosciences beats Lakeshore Biopharma on 7 of the 10 factors compared between the two stocks.

About Lakeshore Biopharma

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

About TuHURA Biosciences

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.